Bumetanide Tablet
NDC Package 60468-002-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Bumetanide tablets is bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This formulation utilizes a tablet delivery system. Marketed by Allphamed Pharbil Arzneimittel Gmbh, this product is identified by NDC 60468-002.

Identification & Billing

NDC Package Code
60468-002-01
Package Description
80000 TABLET in 1 CONTAINER
Product Code
11-Digit Billing Format
60468000201

Clinical Specifications

Proprietary Name
Bumetanide
Non-Proprietary Name
Bumetanide
Substance Name
Bumetanide
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Active Ingredient(s)
Usage Information
Bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. Bumetanide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Regulatory & Marketing

Labeler Name
Allphamed Pharbil Arzneimittel Gmbh
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
08-10-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60468-002-01 identifies a specific commercial package of 80000 tablet in 1 container of Bumetanide (UNFINISHED drug), drug for further processing labeled by Allphamed Pharbil Arzneimittel Gmbh. This tablet is formulated for use and contains bumetanide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allphamed Pharbil Arzneimittel Gmbh on August 10, 2015. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Bumetanide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. Bumetanide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

How is this Allphamed Pharbil Arzneimittel Gmbh product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60468000201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60468-002-01
11-Digit CMS (5-4-2)
60468-0002-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.